Shares of Adaptive Biotechnologies sank 7.2% to $16.20 in pre-market trading after the company unveiled a double-barreled announcement late Sunday: it will separate its cancer-testing diagnostics business from its early-stage drug-discovery arm, and simultaneously raise $250 million through convertible debt — bonds that can later be swapped for stock.

  • The Breakup: A Profitable Unit Gets a Clean Slate, the Other Gets Shown the Door. Adaptive said it will split its Minimal Residual Disease (MRD) diagnostics business — which detects tiny traces of cancer remaining after treatment — from its Immune Medicine drug-discovery platform.

The MRD unit has reached profitability and doubled revenue from $103 million in 2023 to $212 million in 2025.

Going forward, Adaptive will focus on expanding its MRD leadership while pursuing "the optimal path for Immune Medicine outside of Adaptive." Translation: Immune Medicine is up for sale, spinoff, or partnership. That uncertainty is exactly what's spooking investors today.

  • A Quarter-Billion in New Debt Adds Dilution Risk. The company is offering $250 million in convertible senior notes due 2031,

with an option for buyers to purchase an additional $37.5 million.

Proceeds will repay an existing debt agreement with OrbiMed, fund "capped call" transactions designed to limit how much the new bonds dilute existing shareholders, and support up to $25 million in share buybacks. For a company with a roughly $2.6 billion market cap, $250 million-plus in convertible debt is significant — if those bonds convert to stock, current shareholders own a smaller slice of the pie.

  • Strong MRD Numbers Can't Paper Over the Unknowns. In Q1 2026, revenue hit $70.9 million, with MRD contributing $67.1 million — up 53% year-over-year.

Management raised full-year MRD revenue guidance to $260–$270 million. Yet the stock had already pulled back from its 52-week high of $20.76, and several positive clinical and earnings announcements have been followed by mixed to negative share reactions. Investors appear to be pricing in execution risk on both the separation timeline and the debt.

  • The Clock Is Ticking on a Plan Without Details. Adaptive expects to identify its preferred separation path by year-end 2026 — six months with no clarity on whether Immune Medicine gets sold, spun off, or licensed. The company posted a $20 million net loss in Q1 and held $237.2 million in cash. Borrowing $250 million now suggests management wants a war chest before navigating what could be a messy divorce.